记者丨韩璐 编辑丨陈晓平 一家上海抗癌药公司，管理层正式变更。 12月29日，药明巨诺官宣了新董事名单。田丰出任执行董事、行政总裁；董事刘诚升任为董事会主席。 田丰履新，已在两周多前预告，前任CEO刘敏，本月中旬已辞任，他主管运营才1年半左右。 "CAR-T疗法创新却昂贵，一直不在蓬勃周期。" 投资人陈瑜告诉《21CBR》记者，药明巨诺遇到的困境，在于CAR-T的产业环境，新管理层的任务将相当艰巨。 两度换帅 18个月内，田丰是药明巨诺第3位CEO。 他现年48岁，毕业于上海交大医学院，在生物制药工作超过20年。 在职业生涯早期，田丰多在跨国药企就职，曾是辉瑞制药资深国际产品经理，其后转至上海罗氏制药任市场总监，负责了多款肿瘤产品。 2019年后，他跳槽到恒瑞医药，担纲肿瘤事业部市场和医学事务负责人；三年后，出任上海经久生物科技CEO，负责中国区所有运营及战略规划，开始独 当一面。 田丰的上一份工作，在金赛药业任肿瘤事业部总经理，成功引进美适亚®，以前瞻性的准入策略纳入国家医保。 有知情人士向《21CBR》记者透露，上一轮更替，股东方讨论已久，市场有预期；此轮调整，事先未听到风声，相对突然。 药明巨诺一度是细 ...

消息面上，据药明巨诺-B官微消息，12月7日，公司宣布其首款中国自主研发、获批为1类新药的CAR-T 产品倍诺达(瑞基奥仑赛注射液)成功纳入首版国家医保局商业健康保险创新药品目录。 据介绍，倍诺达作为目前国内唯一一款获批三个非霍奇淋巴瘤适应症的CAR-T产品(包括复发难治性大B 细胞淋巴瘤、复发难治性滤泡性淋巴瘤和复发难治性套细胞淋巴瘤)。在本次国家商保创新药目录建立 之前，倍诺达凭借其显著的临床价值，已被纳入100多款普惠保和近100款百万医疗保险，在中国患者中 得到大量临床实践和真实世界研究的充分验证。 药明巨诺-B(02126)早盘涨超9%，截至发稿，涨7.79%，报3.32港元，成交额267.56万港元。 ...

据介绍，倍诺达作为目前国内唯一一款获批三个非霍奇淋巴瘤适应症的CAR-T产品(包括复发难治性大B 细胞淋巴瘤、复发难治性滤泡性淋巴瘤和复发难治性套细胞淋巴瘤)。在本次国家商保创新药目录建立 之前，倍诺达凭借其显著的临床价值，已被纳入100多款普惠保和近100款百万医疗保险，在中国患者中 得到大量临床实践和真实世界研究的充分验证。 智通财经APP获悉，药明巨诺-B(02126)早盘涨超9%，截至发稿，涨7.79%，报3.32港元，成交额267.56 万港元。 消息面上，据药明巨诺-B官微消息，12月7日，公司宣布其首款中国自主研发、获批为1类新药的CAR-T 产品倍诺达(瑞基奥仑赛注射液)成功纳入首版国家医保局商业健康保险创新药品目录。 ...

Core Insights - The introduction of a dual-track payment system for innovative drugs in China marks a significant shift in the healthcare landscape, allowing high-priced CAR-T therapies to enter both the basic medical insurance and commercial insurance innovation drug directories [1][4][5] Group 1: Policy Changes - The National Healthcare Security Administration (NHSA) announced that five CAR-T drugs have passed expert review and are expected to be included in the basic medical insurance and commercial insurance innovation drug directories [1][5] - The establishment of the commercial insurance innovation drug directory provides a separate pathway for high-value, innovative drugs that exceed the basic insurance coverage [1][5] Group 2: Market Dynamics - The dual-track system aims to address the challenges of high-priced drug payments, as traditional basic medical insurance has struggled to accommodate the rising costs of innovative therapies [4][5] - The commercial insurance directory is designed to complement the basic medical insurance directory, allowing companies to choose to apply for either or both directories [5][8] Group 3: CAR-T Drug Insights - The five CAR-T products that passed the review include therapies from companies such as Fosun Kite, WuXi AppTec, and others, with each treatment priced around 1 million yuan per dose [7][8] - The inclusion of CAR-T therapies in the commercial insurance directory is expected to alleviate the financial burden on patients, as seen with Fosun Kite's product, which has been covered by various commercial health insurance plans [7][8] Group 4: Future Implications - The commercial insurance innovation drug directory is anticipated to serve as a transitional phase for innovative drugs before they potentially enter the basic medical insurance directory, based on real-world data and market validation [8] - The establishment of this directory is reshaping the Chinese innovative drug market, making previously inaccessible high-priced therapies more available to a broader patient population [8]